Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03895957
Other study ID # TRR/POIR.01.01.01-00-0636
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 27, 2019
Est. completion date December 31, 2019

Study information

Verified date March 2019
Source Tomorrow Sp. z o.o.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to assess the safety and efficacy of VR Mind and VR Mind + interventions.


Description:

In this study, investigators will test the software developed by Tomorrow Sp. z o. o., named VR Mind and VR Mind+. The software utilizes the concept of virtual reality exposure therapy to treat social anxiety disorder. The aim of the study is to assess the safety and efficacy of VR Mind and VR Mind + interventions.

The research consists of fourteen sessions. The first and the last session will be dedicated to participant assessment. Subsequent sessions 2-13 will be performed according to the therapy protocol for each arm. Control group of participants (active comparative arm) will receive standard treatment for social anxiety disorder - cognitive behavioral therapy based on the protocol developed by the Principal Investigator [protocol adapted from the approach of Clark and Wells (Mayo-Wilson, Dias, Mavranezouli, 2014)]. Experimental group 1 will receive cognitive behavioral therapy with exposure in virtual environment. Experimental group 1 and control group were designed to be as similar as possible, with the exception of the modality for the delivery of exposure. All treatment session will be led by licensed therapist.

Participants of the experimental group 2 will independently conducts the self-therapy process. The intervention will consist of 12 therapeutic sessions. At each of the 12 sessions, the participant will selects a specific scenario of social situations that arouse fear (e.g. public speaking, job interview or other situations from everyday life).

Because of the risk of simulator sickness (e.g., headaches, nausea), exposure trials will last no longer than 20 minutes for each session.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Confirmed DSM-IV-TR criteria for Social Anxiety Disorder (SAD).

- Signing informed consent

- Unchanged doses of psychotropic medications within 3 months prior to baseline assessment and no change is anticipated

Exclusion Criteria:

- occurrence of SAD symptoms inconsistent with DSM-IV-TR criteria and with psychiatric interview (SCID-I; Structured Clinical Interview)

- psychosis,

- bipolar disorder,

- mental retardation

- pregnancy,

- drug addiction,

- alcohol addiction,

- psychoactive substances addiction,

- participating in the experimental session while intoxicated

- (current) neurological treatment of chronic disease of central nervous system,

- epilepsy,

- paroxysmal vertigo,

- presence of suicidal thoughts, tendencies or attempts,

- participant is taking drugs from benzodiazepine group, other sedatives, narcotic drugs

- current CBT treatment for Social Anxiety Disorder

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Virtual Reality Exposure Therapy VR Mind+
Virtual Reality Exposure Self-Therapy led by a participant
Virtual Reality Exposure Therapy VR Mind
Treatment with Virtual Reality Exposure Therapy led by a therapist
Cognitive Behavioral Therapy
Standard treatment for social phobia led by a therapist

Locations

Country Name City State
Poland Gabinet Psychoterapii Warsaw
Poland Tomorrow Sp. z o. o. Warsaw

Sponsors (2)

Lead Sponsor Collaborator
Tomorrow Sp. z o.o. The National Centre for Research and Development

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other Subjective Units of Distress Subjective Units of Distress (SUD) SUD is a subjective measure of perceived fear in certain situation. The scale range is from 0 ("Totally relaxed) to 100 ("Highest distress/fear/anxiety/discomfort that you have ever felt"). Change from session to session with virtual reality exposure during the course of six weeks
Primary Efficacy: Liebowitz Social Anxiety Scale - Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) The scale is composed of 24 items, depicting various social situations. For each item, participants assess their fear (from 1 - "No fear" to 4 - "Severe") and avoidance (from 1 - "Never" to 4 - "Usually"). LSAS has 3 scores, summing the results for particular items - fear (0-72), avoidance (0-72) and total score (0-144). change from baseline: Pre-treatment at session 1, to session 9 (5 weeks) and to post-treatment at session 14 (7 weeks)
Primary Safety: Occurrence and severity of Simulator Sickness - Simulator Sickness Questionnaire (SSQ; Kennedy, Lane, Berbaum, Lilienthal, 1993) Simulator sickness is expected adverse effect of the VR.Total SSQ score equal to or higher than 10 will be used as a preliminary cut-off for simulator sickness (Balk et al., 2013). Individual scores will be corrected for baseline (pre-VR) symptom severity. Only items with a pre-VR - post-VR increase will contribute to a final SSQ score. All post-intervention SSQ scores >10 will be analyzed further for its association with study drop-outs and other intervention required. The adverse effect will be classified as:
mild (no intervention required),
moderate (any intervention needed, e.g. session termination),
severe (hospitalization required),
life-threatening / death.
Some of the symptoms of anxiety may produce similar side effects as a simulator sickness. The results obtained in this case will be false positive. Therefore assessment of side effects for each case will be verified if the increase in SSQ score was triggered by rapid relapse of phobia symptoms.
Change from session to session with virtual reality exposure: at session 1, session 7 (4 weeks), session 8 (4 weeks), session 10 (5 weeks), session 11 (6 weeks) and session 12 (6 weeks)
Secondary Clinical Global Impression Clinical Global Impression (CGI; Guy, 1976) - is a single item, 7 point scale used by clinicians to assess the severity of illness, where 1 is labeled as "Normal, not at all ill" and 7 is labeled as "Among the most extremely ill patients". Pre-treatment at session 1
Secondary Clinician Global Impressions of Improvement Global measure of change in severity of symptoms, ranging from 1 labeled as " Very much improved" to 7 labeled as "Very much worse". Post-treatment, approximately 7 weeks after initial session
Secondary Patient Global Impression Patient Global Impression - is a single item, 4 point scale used by patients to assess their impression of severity of their illness and quality of their functioning in everyday life, where 1 is labeled as "Normal" and 4 is labeled as "Severe". Pre-treatment at session 1
Secondary Patient Global Impressions of Improvement Global measure of change in severity of symptoms, where 1 is labeled as "No change" and 7 is labeled as " Very much improved ". Post-treatment, approximately 7 weeks after initial session
Secondary Beck Depression Inventory A 21-question multiple-choice self-report inventory for measuring the severity of depression. Each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs used differ from the original:
0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression
Pre-treatment at session 1 to post-treatment at session 14 (7 weeks)
See also
  Status Clinical Trial Phase
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01570400 - Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT N/A
Recruiting NCT01388231 - Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Phase 2/Phase 3
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00380731 - Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia N/A
Completed NCT00434759 - Social Phobia Intervention Study of Mannheim N/A
Completed NCT03647605 - Pilot Study: VR Mind and VR Mind+ Intervention N/A
Not yet recruiting NCT03241277 - Nonsurgical Periodontal Treatment in Patients With Social Phobia N/A
Completed NCT02648737 - Cognitive Behavioural Therapy for Anxiety Disorders in PD N/A
Completed NCT02294409 - Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis N/A
Terminated NCT01979263 - Attention Bias Modification Treatment for Anxious Youth N/A
Completed NCT01463137 - Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder N/A
Completed NCT00774150 - Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study N/A
Completed NCT00264654 - Long-term Study Of Paroxetine in Women and Men Phase 3
Completed NCT00326430 - Residential Cognitive and Interpersonal Therapy for Social Phobia Phase 2/Phase 3
Completed NCT00000389 - Treatment for Anxiety in Children Phase 3
Completed NCT00397722 - Treatment Of Patients With Social Anxiety Disorder Phase 2
Completed NCT02678624 - Project Collabri for Treatment of Anxiety N/A
Completed NCT00564967 - A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Phase 3
Completed NCT00403962 - A Combination Therapy In Patients With Social Anxiety Disorder Phase 2